Dr. Tubin is a 44-years-old board-certified radiation oncologist and scientific investigator from Austria, currently working as a director of clinical radiobiology and scientific co-director at the MedAustron Center for Ion Therapy and Research (AUT). His research interests include immunomodulation using carbon-ions, induction of the immune-mediated non-targeted effects of radiotherapy: bystander and abscopal effects. Currently, he is a principle investigator of ongoing national and international, multi-centric, prospective studies on intentional induction of the abscopal and bystander effects among patients with oligometastatic and unrescetable bulky tumors. He graduated at the University of Rome (ITA) “La Sapienza” in 2008, and then finished his residency also in Rome in 2012. During 2010-2011, he joined the University of Miami (USA) performing the preclinical in vitro and in vivo research on radiation-induced bystander effects. The finding of those studies led to the development of a novel and unique technique for partial tumor irradiation targeting the hypoxic segment of bulky unresectable tumors for the clinical exploitation of bystander and abscopal effects. He was several times awarded for the best abstract presenting the preclinical and clinical findings related to this novel approach (2014 in Forli, ITA; 2016 in Klagenfurt, AUT; 2018 in Dublin, IRL; 2018 in Rimini, ITA; 2019 in Vienna, AUT; 2022 in Villach, AUT; 2022 in Barcelona, ESP). Dr. Tubin is currently leading the ESTRO focus group for innovative and unconventional radiotherapy techniques. He is adjunct professor by Albert Einstein College of Medicine in New York.